| Delta group (n = 103) | Mtb group (n = 52) | HIV group (n = 11) | Omicron group (n = 384) | P1-value | P2-value | P3-value | P4-value |
---|---|---|---|---|---|---|---|---|
Characteristics | ||||||||
Median (interquartile) age (years) | 41 (28–57) | 49 (27–62) | 47 (32–51) | 18 (17–34) | 0.880 | 0.331 | 0.715 | 0 |
Age groups (years) | Â | Â | Â | Â | 0.25 | 1.0 | 0.443 | 0 |
 ≤ 18 | 11 (11%) | 2 (4%) | 1 (9%) | 235 (61%) | ·· | ·· | ·· | ·· |
 19–40 | 40 (39%) | 22 (42%) | 2 (18%) | 72 (19%) | ·· | ·· | ·· | ·· |
 41–65 | 39 (38%) | 18 (35%) | 8 (73%) | 58 (15%) | ·· | ·· | ·· | ·· |
 ≥ 66 | 13 (13%) | 10 (19%) | 0 | 19 (5%) | ·· | ·· | ·· | ·· |
Male sex | 45 (44%) | 37 (71%) | 8 (73%) | 162 (42%) | 0.0012 | 0.066 | 0.0495 | 0.784 |
Familial cluster | 28 (27%) | 8 (15%) | 0 | 166 (46%) | 0.10 | 0.10 | 0.371 | 0.001 |
Coexisting conditions | 34 (33%) | 17 (33%) | 6 (55%) | 39 (10.2%) | 0.935 | 0.246 | 0.306 | < 0.0001 |
 Diabetes | 14 (14%) | 10 (19%) | 5 (45%) | 10 (3%) | 0.36 | 0.0029 | 0.039 | 0 |
 Hypertension | 12 (12%) | 3 (6%) | 1 (9%) | 23 (6%) | 0.38 | 1.0 | 0.546 | 0.048 |
 Cardiovascular disease | 8 (8%) | 3 (6%) | 0 | 6 (1.6%) | 0.90 | 1.0 | 1.0 | 0.003 |
 Chronic obstructive pulmonary disease | 0 | 1 (2%) | 0 | 0 | 0.34 | ·· | 1.0 | ·· |
Number of vaccination doses |  |  |  |  | < 0.0001 | 0.001 | 0.078 | < 0.0001 |
 0 | 40 (39%) | 34 (65%) | 11 (100%) | 2 (1%) | ·· | ·· | ·· | ·· |
 1 | 7 (7%) | 16 (31%) | 0 | 11 (3%) | ·· | ·· | ·· | ·· |
 2 | 53 (51%) | 2 (4%) | 0 | 346 (90%) | ·· | ·· | ·· | ·· |
 3 | 1 (1%) | 0 | 0 | 21 (5%) | ·· | ·· | ·· | ·· |
Fever | 36 (35%) | 11 (21%) | 3 (27%) | 96 (25%) | 0.21 | 0.86 | 1.0 | 0.038 |
Highest temperature, °C |  |  |  |  | 0.13 | 0.86 | 1.0 | 0.083 |
 < 37.3 | 67 (65%) | 41 (79%) | 8 (73%) | 283 (74%) | ·· | ·· | ·· | ·· |
 37.3–38 | 17 (17%) | 5 (10%) | 1 (9%) | 48 (12%) | ·· | ·· | ·· | ·· |
 > 38 | 19 (18%) | 6 (11%) | 2 (18%) | 53 (14%) | ·· | ·· | ·· | ·· |
Cough | 26 (25%) | 14 (27%) | 3 (27%) | 240 (63%) | 0.82 | 1.0 | 1.0 | 0 |
Expectoration | 16 (16%) | 5 (10%) | 1 (9%) | 112 (29%) | 0.31 | 0.90 | 1.0 | 0.005 |
Myalgia or fatigue | 9 (9%) | 19 (36%) | 4 (36%) | 30 (6%) | 0.0005 | 0.098 | 1.0 | 0.002 |
Nasal congestion | 7 (7%) | 9 (17%) | 0 | 96 (25%) | 0.042 | 1.0 | 0.31 | 0 |
Loss of smell and taste | 2 (2%) | 5 (10%) | 2 (18%) | 4 (1%) | 0.078 | 0.046 | 0.769 | 0.816 |
Headache | 3 (3%) | 3 (6%) | 0 | 7 (2%) | 0.67 | 1.0 | 1.0 | 0.763 |
Dyspnea | 0 | 0 | 0 | 3 (0.8%) | ·· | ·· | ·· | 1 |
Severity score |  |  |  |  | 0.706 | 0.519 | 0.788 | < 0.0001 |
 4 | 84 (81%) | 40 (77%) | 8 (73%) | 380 (99%) | ·· | ·· | ·· | ·· |
 5 | 17 (17%) | 10 (19%) | 3 (27%) | 4 (1%) | ·· | ·· | ·· | ·· |
 9 | 2 (2%) | 2 (4%) | 0 |  | ·· | ·· | ·· | ·· |
The incubation period (days) | 3 (2–7) (n = 81) | 2 (1–3) (n = 48) | 4 (2–6) (n = 8) | 2 (1–2) (n = 97) | 0.31 | 0.0004 | 0.815 | 0 |
Time from illness onset to first hospital admission (days) | 2.5 (0–5.0) | 5 (4–5) | 3 (2–4) | 2 (1–3) (n = 362) | 0.003 | < 0.0001 | 0.999 | 0.840 |